A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 177 participants.
Also called NCT01262638
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 177 participants
- Sponsor
- Registry
-
NCT01262638
-
- Other papers using this trial's data
- Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01262638. Randomized; quadruple masking; primary purpose treatment. Start 2010-12 (registry gives no type); primary completion 2011-08-23 (actual). Results posted on 2021-03-16.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
- Condition
- Dyslipidemia
- Intervention (Drug)
- ETC-1002
- Intervention (Drug)
- Placebo
- Lead sponsor
- Esperion Therapeutics, Inc.
Record details
- Record id
cardio:ct-nct01262638- Content hash
a65d76cb6a3a61fd99dffed8f8f4265c5c81ec6034c510f9cd8073d0f2e9d638